Company Overview of Polyphor Ltd
Polyphor Ltd., a pharmaceutical company, engages in the discovery and development of macrocycle drugs addressing high unmet medical needs. Its product pipeline includes CXCR4 antagonist POL6326, a potent and selective antagonist of the chemokine receptor CXCR4 that blocks the interaction with the ligand stromal cell-derived factor 1 resulting in the mobilization of stem cells from the bone marrow into the circulating blood; Antibiotic POL7080, a pseudomonas specific antibiotic with a novel mode of action; and Neutrophil elastase inhibitor POL6014, a selective and reversible inhibitor of human neutrophil elastase for the treatment of respiratory diseases, such as chronic obstructive pulmonary...
Founded in 1996
Key Executives for Polyphor Ltd
Co-Founder and Chief Scientific Officer
Head of the Internal Services
Compensation as of Fiscal Year 2016.
Polyphor Ltd Key Developments
Polyphor Announces Executive Changes
Mar 20 17
Polyphor has named Dr. Debra Baker as its new chief medical and development officer. The role focuses on clinical strategy and drug development. Dr. Baker arrives at Polyphor from Novartis, where she held several positions including global head of medical affairs, development head for infectious diseases, transplants and immunology, and global head of clinical operations and services. Dr. Baker succeeds Leon Hootftman, who leaves Polyphor to take a new position.
Polyphor Appoints Debra Barker as Chief Medical and Development Officer, Effective May 01, 2017
Mar 6 17
Polyphor announced the appointment of Dr. Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO). Dr. Barker joins Polyphor effective May 01, 2017. Her significant experience in infectious and respiratory diseases and immunology and her leadership make her the perfect fit and will be instrumental to Polyphor's Pharma business.
Polyphor Ltd. Receives CHF 2.3 Million Award from Wellcome Trust to Accelerate the Development of a Novel Antibiotic Drug Class
Feb 9 17
Polyphor Ltd. announced that it has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates. These are based on Polyphor's new product class, the Outer Membrane Protein Targeting Antibiotics, which has shown outstanding efficacy against the most resistant strains of Gram-negative pathogens. The Seeding Drug Discovery Award will help support the development of novel antibiotics over the next 18 - 24 months.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries